Kazan Özgür, Çulpan Meftun, Efiloğlu Özgür, Atiş Gökhan, Yildirim Asıf
Department of Urology, Kocaeli State Hospital, Kocaeli, Turkey.
Department of Urology, Istanbul Medeniyet University School of Medicine, Istanbul, Turkey.
Turk J Urol. 2021 Nov;47(6):495-500. doi: 10.5152/tud.2021.21278.
The protective effect of androgen deprivation therapy (ADT) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a novel hypothesis. ADT may protect patients with prostate cancer through the inhibition of androgen receptor-dependent transmembrane serine protease type 2. We analyzed the role of ADT on SARS-CoV-2 infection risk and disease severity.
Between August 2020 and June 2021, patients with prostate cancer were included in our study. Patients were divided into two groups as men receiving ADT or not. Patients' characteristics such as prostate cancer grade and stage, comorbidities, SARS-CoV-2 infection status, and infection severity were assessed. SARS-CoV-2-infected close relatives and patients' compliance with the precautions against SARSCoV- 2 were also analyzed.
A total of 365 patients, 138 (37.8%) with ADT and 227 (62.2%) without ADT, were included in our analysis. Patients with ADT were older (71.8 vs 66.9 years, P ¼ .001) and had a higher rate of chronic obstructive pulmonary disease (11.6% vs 5.7%, P ¼ .044). Patients receiving ADT were more often locally advanced and metastatic (80.4% vs 32.6%, P ¼ .001). SARS-CoV-2 infection rates were statistically similar between patients who received and did not receive ADT (9.4% vs 13.2%, P ¼ .275, respectively). There was no significant difference between two groups in terms of hospitalization rates (2.9% vs 0.9%, P ¼ .205). In multivariate analysis, the presence of SARS-CoV-2-infected close relatives and precautions score were only independent predictors for both risk of SARS-CoV-2 infection and infection severity.
We could not find any effect of ADT on risk and severity of SARS-CoV-2 infection. SARSCoV- 2 infection and hospitalization rates were similar between patients with and without ADT.
雄激素剥夺疗法（ADT）对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的保护作用是一个新的假说。ADT可能通过抑制雄激素受体依赖性跨膜丝氨酸蛋白酶2来保护前列腺癌患者。我们分析了ADT对SARS-CoV-2感染风险和疾病严重程度的作用。
2020年8月至2021年6月期间，前列腺癌患者被纳入我们的研究。患者分为接受ADT和未接受ADT两组。评估患者的特征，如前列腺癌分级和分期、合并症、SARS-CoV-2感染状况以及感染严重程度。还分析了SARS-CoV-2感染的近亲以及患者对SARS-CoV-2预防措施的依从性。
我们的分析共纳入365例患者，其中138例（37.8%）接受ADT，227例（62.2%）未接受ADT。接受ADT的患者年龄更大（71.8岁对66.9岁，P = 0.001），慢性阻塞性肺疾病发生率更高（11.6%对5.7%，P = 0.044）。接受ADT的患者更常为局部晚期和转移性（80.4%对32.6%，P = 0.001）。接受和未接受ADT的患者之间SARS-CoV-2感染率在统计学上相似（分别为9.4%对13.2%，P = 0.275）。两组的住院率无显著差异（2.9%对0.9%，P = 0.205）。在多变量分析中，SARS-CoV-2感染的近亲的存在和预防措施评分是SARS-CoV-2感染风险和感染严重程度的仅有的独立预测因素。
我们未发现ADT对SARS-CoV-2感染风险和严重程度有任何影响。接受和未接受ADT的患者之间SARS-CoV-2感染率和住院率相似。
